Scientists test Triple-Threat drug cocktail against tough cancers
NCT ID NCT04317105
Summary
This study is testing a new combination of three drugs—copanlisib, nivolumab, and ipilimumab—for adults with advanced solid tumors that have spread and have specific genetic changes. The goal is to see if adding copanlisib to two existing immunotherapy drugs is safe and works better to control the cancer. Researchers will monitor patients closely for side effects and to see if their tumors shrink or stop growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
University of Texas Medical Branch
Galveston, Texas, 77555-0565, United States
-
University of Texas at Austin
Austin, Texas, 78712, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.